Back to top
more

Better trading starts here.

Brokerage Reports

Research for MREO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

2 items in cart

View Cart/Checkout

MEREO BIOPHARMA [MREO]

Reports for Purchase

Showing records 1 - 17 ( 17 total )

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 1

12/18/2020

Company Report

Pages: 2

Setrusumab partnered with Ultragenyx

Provider: Trinity Delta

Analyst: GREGOREK L

Price: 10.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 2

12/09/2020

Company Report

Pages: 11

Targeting TIGIT thoughtfully

Provider: Trinity Delta

Analyst: GREGOREK L

Price: 25.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 3

12/09/2020

Company Report

Pages: 11

Targeting TIGIT thoughtfully

Provider: Trinity Delta

Analyst: GREGOREK L

Price: 25.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 4

10/12/2020

Company Report

Pages: 8

H120 results and corporate review

Provider: TRINITY DELTA

Analyst: GREGOREK L

Price: 25.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 5

09/02/2020

Company Report

Pages: 22

TIGIT programme starts the next chapter

Provider: TRINITY DELTA

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 6

09/02/2020

Company Report

Pages: 22

TIGIT programme starts the next chapter

Provider: TRINITY DELTA

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 7

06/04/2020

Daily Note

Pages: 2

Private placement raises $70m (#56m)

Provider: TRINITY DELTA

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 8

02/11/2020

Company Report

Pages: 2

Funding deals worth up to $33m announced

Provider: TRINITY DELTA

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 9

01/15/2020

Daily Note

Pages: 2

Additional ASTEROID data supports progression

Provider: TRINITY DELTA

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 10

01/13/2020

Company Report

Pages: 2

Oncologie takes global licence to Navi

Provider: TRINITY DELTA

Analyst: COOPER M

Price: 10.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 11

01/03/2020

Company Report

Pages: 24

Underappreciated but not unloved

Provider: TRINITY DELTA

Analyst: COOPER M

Price: 75.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 12

11/25/2019

Company Report

Pages: 10

Setrusumab ready to advance into pivotal studies

Provider: TRINITY DELTA

Analyst: COOPER M

Price: 25.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 13

11/11/2019

Company Report

Pages: 2

Setrusumab set to advance

Provider: TRINITY DELTA

Analyst: COOPER M

Price: 10.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 14

09/19/2019

Company Report

Pages: 3

Entering an important 12 month period

Provider: TRINITY DELTA

Analyst: COOPER M

Price: 10.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 15

09/19/2019

Company Report

Pages: 3

Entering an important 12 month period

Provider: TRINITY DELTA

Analyst: COOPER M

Price: 10.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Medical - Biomedical and Genetics

Record: 16

07/16/2019

Company Report

Pages: 2

Accelerated approval path for NAVI

Provider: TRINITY DELTA

Price: 10.00

Research Provided by a Third Party

Company: MEREO BIOPHARMA

Industry: Unclassified

Record: 17

05/31/2019

Company Report

Pages: 4

Encouraging interim BPS-804 data in OI

Provider: TRINITY DELTA

Price: 10.00

Research Provided by a Third Party